Navigation Links
Gene Variants Linked to Early Heart Attack Discovered

Two gene variations have been discovered by scientists at UCSF, Celera Genomics and The Cleveland Clinic which have been linked to an increased risk// for early heart attack, or myocardial infarction (MI).

One of the genes, known as VAMP8, normally expresses a protein essential for early stages of clotting. When clotting occurs in a coronary blood vessel, it can lead to heart attack. Knowing gene mutations that increase heart attack risk can help identify people at risk and clarify molecular changes involved in heart disease. This knowledge can lead to new potential drug targets to treat the disease.

The research will be reported in the July 2006 edition of Arteriosclerosis, Thrombosis, and Vascular Biology and is being made available online May 11, 2006 on the publication's website at http://atvb.ahajournals.org/.

A person with either of the two gene variants has about twice the risk of early heart attack as someone with neither, the research showed. The retrospective study analyzed clinical records and gene variations in more than 2,000 patients and controls in three independent investigations. All study participants were Caucasian, and the average age of heart attack among the cardiac patients was under 60.

Neither of the two genetic variants, known as single nucleotide polymorphisms or (SNPs), has previously been associated with heart attack. VAMP8 is involved in platelet aggregation. The other gene, HNRPUL1, encodes a protein involved in RNA activity.

Celera Genomics (NYSE:CRA) is an Applera Corporation business.

"This research and other large, carefully controlled studies can provide valuable insights into genetic contributions to early-onset heart attack," said John P. Kane, MD, PhD, professor of medicine at UCSF and associate director of UCSF's Cardiovascular Research Institute. "A number of studies have identified genes linked to increased heart attack risk, but many of the studies have been m ade with a single cohort of patients and have not been replicated.

The new study involved three sequential cohorts, and applied a statistical analysis that increases the likelihood that these are indeed true associations." Kane, a collaborator and a co-author on this study, was senior author on a paper published last fall with many of the Celera colleagues, identifying four gene variants associated with heart attacks. Kane and his UCSF colleagues have identified nine genes linked to increased heart attack risk thus far.

He suspects that the newly discovered variant of VAMP8 either speeds the clotting process, triggers it too early or allows clotting to continue too long.

"We are now eager to screen the population for people with two copies of this gene and study its action at the molecular level," Kane said. "VAMP 8 could be a target for a new drug."

Large scale studies like this one, with well-characterized samples from carefully selected patients, hold significant promise to enable the development of new diagnostics and targeted therapeutics, the scientists say.

"In order for genetic marker studies to translate into diagnostic tests with significant medical impact, discovery study results must be reproducible and applicable to a wide group of people," said Tom White, PhD, chief scientific officer at Celera Genomics. "Too often, when new markers are reported, the disease association cannot be confirmed because the study used a small sample set. In addition, a spurious disease association could be found due to chance alone if a large number of SNPs are not tested."

The size of this study and the identification of VAMP8, coupled with other prospective studies of the general population underway at Celera, are providing valuable insight toward the development of a "Genetic Risk Score" that is expected to identify individuals at elevated risk for heart disease, White said.

Celera evaluated DN A samples from more than 2,000 individuals in three studies to compare patterns of genetic variation in people with a history of early-onset MI to those with no history of heart disease. The results were significant in all three studies.

The key finding of the study was that variants of the VAMP 8 and HNRPUL1 genes were associated with early-onset MI, and the same variants were associated with risk in all three studies. Each of these gene variants individually confers an increased risk for MI that is comparable to conventional risk factors such as smoking, high blood pressure and elevated cholesterol levels.

These genetic markers were identified through a genome-wide study of 11,647 single SNPs in 7,136 genes. The study focused on SNPs that could influence gene function in order to increase the likelihood of identifying disease-causing gene variants. These were tested for association with early-onset MI in three case-control studies with a total of 821 cases and 1,200 controls.

Two of the samples drew on the very large and complete collection of clinical records, blood samples, DNA analysis and other records of more than 27,000 heart disease patients stored and studied as part of the Genomics Resource in Arteriosclerosis at UCSF's Cardiovascular Research Institute (CVRI). The third sample comes from a collection at The Cleveland Clinic

The study is a collaboration of UCSF, Celera, The Cleveland Clinic Foundation, Case Western Reserve University and Brigham Young University.

First author on the paper is Dov Shiffman, PhD, senior staff scientist at Celera. Co-authors at Celera are James J. Devlin, PhD, director of cardiovascular research, and Charles Rowland, Judy Louie, May Luke, Lance Bare , Joel Bolnick, Bradford Young and Joseph Catanese.

Colleagues and co-authors with Kane at UCSF's CVRI are Mary Malloy, MD, UCSF professor of medicine and pediatrics, and Clive Pullinger, PhD, adjunct associate prof essor of genetics. Other co-authors on the paper are Stephen Ellis, MD, director of the Sones Cardiac Department of Cardiovascular Medicine and professor of medicine at The Cleveland Clinic, Charles Stiggins at Brigham Young University, and Eric Topol at Case Western Reserve University.

Source: Eurekalert
'"/>




Related medicine news :

1. Striking a Gold Mine: H5N1 Vaccine may Serve as an Antidote for Mutants and Variants
2. Susceptibility Of TB In Humans Might Be Due To Three Human Gene Variants
3. Gene Variants Linked to Preterm Birth in Hispanic Women
4. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
5. Cough Syrup Ingredient Linked to Stroke
6. Irregular Periods Linked to Diabetes
7. Hormones Linked To Migraines
8. Triglycerides Linked To Stroke Risk
9. Smoking Linked To Low Infant Birth Weight
10. Nausea Linked To Anxiety And Depression
11. Painkiller Linked to Deaths
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated a new ... This is the first time that Coolsculpting is being used for for more than ... to ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
(Date:5/26/2016)... ... 2016 , ... There are many ways to cook a hot dog, but ... Americans prefer their dogs straight off the grill. Of the 90 percent of Americans ... to cook a hot dog, far outpacing other cooking methods such as steaming (12 ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016  NxStage Medical, Inc. (Nasdaq: NXTM ... renal care, today announced that Jeffrey H. Burbank ... following schedule of investor conferences. Where applicable, a webcast ... http://ir.nxstage.com/ .   ... NY           Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior ... executive officer, today. In his new role, Marziani will lead the company,s business development ... professionals to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... 2016 Los innovadores de ... mundo, introduce catéteres para la intervención de extremidades ... compañía global especializada en el suministro de soluciones ... cartera incluyendo productos para tratar la enfermedad arterial ... son los dispositivos de primera entrada de la ...
Breaking Medicine Technology: